Stock 600645 VCANBIO CELL & GENE ENGINEERING CORP., LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials Vcanbio Cell & Gene Engineering Corp., Ltd

Equities

600645

CNE000000545

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
17.8 CNY +4.89% Intraday chart for Vcanbio Cell & Gene Engineering Corp., Ltd +8.21% -12.19%
Apr. 25 Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Apr. 25 Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 7,148 7,923 9,176 11,811 7,960 9,485
Enterprise Value (EV) 1 6,741 7,025 8,175 10,698 6,708 8,020
P/E ratio 108 x 154 x -72.6 x 76.5 x 70.9 x 88.1 x
Yield - - - - - -
Capitalization / Revenue 5.41 x 5.71 x 6.96 x 7.69 x 5.12 x 5.97 x
EV / Revenue 5.11 x 5.07 x 6.2 x 6.97 x 4.31 x 5.04 x
EV / EBITDA 44.7 x 26 x 42.7 x 48.7 x 27.2 x 27.3 x
EV / FCF -81.6 x 83.5 x 58.4 x 54 x 47.5 x 41.4 x
FCF Yield -1.22% 1.2% 1.71% 1.85% 2.11% 2.42%
Price to Book 2.58 x 2.36 x 2.7 x 3.41 x 2.24 x 2.37 x
Nbr of stocks (in thousands) 440,161 467,970 467,949 467,949 467,949 467,949
Reference price 2 16.24 16.93 19.61 25.24 17.01 20.27
Announcement Date 4/29/19 4/28/20 4/23/21 4/24/22 4/25/23 4/25/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 1,321 1,387 1,319 1,535 1,555 1,590
EBITDA 1 150.7 270.2 191.5 219.6 246.6 293.8
EBIT 1 44.16 178.3 94.26 124.4 142.9 180
Operating Margin 3.34% 12.86% 7.15% 8.11% 9.19% 11.32%
Earnings before Tax (EBT) 1 104.5 113.5 -89.09 223 155.2 132.6
Net income 1 59.25 49.69 -126.9 155.3 113 106.5
Net margin 4.49% 3.58% -9.62% 10.12% 7.27% 6.7%
EPS 2 0.1500 0.1100 -0.2700 0.3300 0.2400 0.2300
Free Cash Flow 1 -82.58 84.1 140.1 198 141.3 193.9
FCF margin -6.25% 6.06% 10.62% 12.9% 9.09% 12.2%
FCF Conversion (EBITDA) - 31.12% 73.16% 90.15% 57.29% 66.01%
FCF Conversion (Net income) - 169.24% - 127.47% 125.03% 182.19%
Dividend per Share - - - - - -
Announcement Date 4/29/19 4/28/20 4/23/21 4/24/22 4/25/23 4/25/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 407 898 1,002 1,113 1,252 1,465
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -82.6 84.1 140 198 141 194
ROE (net income / shareholders' equity) 2.21% 1.67% -3.65% 4.3% 2.97% 2.64%
ROA (Net income/ Total Assets) 0.62% 2.39% 1.21% 1.57% 1.73% 2.1%
Assets 1 9,509 2,080 -10,518 9,899 6,525 5,061
Book Value Per Share 2 6.300 7.170 7.260 7.400 7.600 8.540
Cash Flow per Share 2 1.330 1.350 2.270 2.560 2.980 3.660
Capex 1 128 123 91.7 128 99.2 88.6
Capex / Sales 9.7% 8.87% 6.95% 8.32% 6.38% 5.57%
Announcement Date 4/29/19 4/28/20 4/23/21 4/24/22 4/25/23 4/25/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Diagnostic & Testing Substances

1st Jan change Capi.
VCANBIO CELL & GENE ENGINEERING CORP., LTD Stock Vcanbio Cell & Gene Engineering Corp., Ltd
-12.19% 1.15B
BIOMÉRIEUX Stock bioMérieux
-1.89% 12.56B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-9.59% 7.68B
DIASORIN S.P.A. Stock DiaSorin S.p.A.
-1.31% 5.29B
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+21.82% 5.18B
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
+0.02% 4.57B
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-50.89% 3.29B
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+6.42% 2.6B
VITROLIFE AB Stock Vitrolife AB
-10.02% 2.2B
GUANGZHOU WONDFO BIOTECH CO.,LTD Stock Guangzhou Wondfo Biotech Co.,Ltd
-8.29% 1.79B
Diagnostic & Testing Substances
  1. Stock Market
  2. Equities
  3. 600645 Stock
  4. Financials Vcanbio Cell & Gene Engineering Corp., Ltd